By Lisa Kerner
Charlotte, N.C., Nov. 13 - Yaupon Therapeutics said it closed a $4 million round of series B financing and will use the proceeds to support continued development of its multiple clinical programs in the treatment of lymphoma, addiction and neuropathic pain.
Osage Ventures led the round and was joined by BioAdvance Greenhouse Fund, Ben Franklin Technology Partners of Philadelphia and TDH Capital.
"Our lead product is now enrolling patients for a pivotal study and is continuing to show great promise as we advance toward Food and Drug Administration filing and commercialization," president and chief executive officer Robert Alonso said in a company news release.
David Drahms, vice president of Osage Ventures, and Barbara Schilberg, chief executive officer of BioAdvance, will join Yaupon's board of directors.
Yaupon is a privately held specialty pharmaceutical company located in Radnor, Pa.
| Issuer: | Yaupon Therapeutics
|
| Issue: | Series B financing
|
| Amount: | $4 million
|
| Investors: | Osage Ventures (lead), BioAdvance Greenhouse Fund, Ben Franklin Technology Partners of Philadelphia, TDH Capital.
|
| Announcement date: | Nov. 13
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
